![(1S)-1,5-脱氢-1-C-[3-[[5-(4-氟苯基)-2-噻吩基]甲基]-4-甲基苯基]-D-葡萄糖醇](https://stcdn.activebiopharma.com/active/ABP000358.png)
化学名称 : (1S)-1,5-脱氢-1-C-[3-[[5-(4-氟苯基)-2-噻吩基]甲基]-4-甲基苯基]-D-葡萄糖醇
CAS : 842133-18-0
英文名称: Canagliflozin/
英文同义词: CANAGLIFLOZIN
溶解度:Unknown
储存条件:at -20℃ 2 years
生物活性
Canagliflozin is an experimental drug being developed by Johnson & Johnson for the treatment of type 2 diabetes.[1][2] It is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.[3]
参考文献
吡美莫司
137071-32-0
恩扎妥林
170364-57-5
乙基-2-氨基-6-溴-4-(1-氰基-2-乙氧基-2-甲酰)-4H-苯并呋喃-3-羧酸
65673-63-4
RO0335
867365-76-2